Will Hcg Make You Fertail Again in Men
Fertil Steril. Author manuscript; bachelor in PMC 2018 Feb 1.
Published in terminal edited form as:
PMCID: PMC5292276
NIHMSID: NIHMS822667
Age and Elapsing of Testosterone Therapy Predict Time to Render of Sperm Count afterwards hCG Therapy
Taylor P. Kohn
aBaylor College of Medicine, Houston, TX
Matthew R. Louis
aBaylor College of Medicine, Houston, TX
Stephen One thousand. Pickett
bSection of Economic science, Rice University, Houston, TX
Marker C. Lindgren
cUniversity of Oklahoma Higher of Medicine, Department of Urology, Oklahoma City, OK
Jaden R. Kohn
aBaylor College of Medicine, Houston, TX
Alexander W. Pastuszak
dCenter for Reproductive Medicine, Baylor Higher of Medicine, Houston, TX
due eastScott Department of Urology, Baylor College of Medicine, Houston, TX
Larry I. Lipshultz
dCenter for Reproductive Medicine, Baylor Higher of Medicine, Houston, TX
eastwardScott Department of Urology, Baylor College of Medicine, Houston, TX
Abstract
Objective
To determine factors that influence sperm recovery after testosterone-associated infertility.
Design
Clinical retrospective study.
Setting
Academic male-infertility urology clinic.
Patient(south)
Sixty-half-dozen men who presented with infertility after testosterone use.
Intervention(south)
Testosterone (T) abeyance and combination high-dose man chorionic gonadotropin (hCG) and selective estrogen modulator (SERM) therapy.
Main Effect Measure(s)
Whether patients successfully achieved or failed to achieve a total motile count (TMC) of greater than 5 million sperm within 12 months of T cessation and initiation of therapy.
Result(due south)
A TMC of greater than v million sperm was accomplished by 46 men (70%). Both increased age and elapsing of testosterone employ straight correlated with time to sperm recovery at both 6 and 12 months of hCG/SERM therapy. Age more consistently express sperm recovery, while elapsing of testosterone use had less influence at 12 months than at 6 months. Only 64.8% of azoospermic men achieved a TMC greater than 5 1000000 sperm at 12 months, compared with 91.7% of cryptozoospermic men, notwithstanding this did not predict a failure of sperm recovery.
Determination(s)
Increasing age and elapsing of testosterone utilise significantly reduce the likelihood of recovery of sperm in the ejaculate, based on a criterion of a TMC of 5 million sperm, at half-dozen and 12 months. Physicians should be cautious in pursuing long-term testosterone therapy, particularly in men who yet desire fertility. Using these findings, physicians tin counsel men regarding the likelihood of recovery of sperm at 6 and 12 months.
Keywords: Infertility, Testosterone, Sperm, Azoospermia, Human chorionic gonadotropin, Spermatogenesis-Blocking Agents
Sheathing
In this retrospective analysis of 66 men with testosterone-associated infertility, we found that duration of testosterone therapy and age at presentation are straight correlated with time to sperm recovery.
INTRODUCTION
The utilise of exogenous testosterone (T) in the treatment of hypogonadism has known risks with regards to male infertility. Serum testosterone levels in men begin to decrease in an age-dependent way starting in the late 30'south (ane–3), and the number of testosterone prescriptions has drastically increased in recent years, from 1.2 million patients in 2010 to 2.2 meg patients in 2013 (4). Of men receiving testosterone therapy (TTh), 12.4% were younger than 39 years old, indicating that a large number of men seek TTh during the reproductive years (5). One report institute that vii% of male patients seeking intendance for infertility were on TTh at the fourth dimension of their visit, and concomitant TTh was the fourth most common etiology of male infertility in the two large infertility practices in the study (6). Coupled with the increase in T prescriptions, physicians are oftentimes failing to inform patients of the risk of testosterone-induced infertility, in part due to a lack of knowledge of the fertility-related adverse effects of TTh. In a 2010 survey of urologist members of the American Urological Association, 25% incorrectly believed that TTh would improve a male'south fertility (7); such beliefs likely contribute to the growing number of men with T-induced infertility (eight).
Exogenous T inhibits spermatogenesis by suppressing secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary gland, limiting the signals required for endogenous testosterone production and spermatogenesis (9). Thus, the use of testosterone by younger men increasingly intersects with their reproductive potential for many men, and approaches to predicting and mitigating the negative furnishings of testosterone on fertility are needed.
Several studies have demonstrated that cessation of TTh in men seeking fertility treatment tin lead to a render to baseline sperm concentrations (6, ten–12). Withal, the time for render of sperm to the ejaculate in quantities sufficient for fertility remains unclear. In a pooled assay of 30 studies using testosterone as a curt-term hormonal contraceptive in eugonadal men, Liu et al. demonstrated that the average probability of sperm recovery to twenty meg sperm / mL was 67% inside vi months, 90% within 12 months, 96% inside 16 months, and 100% within 24 months, only suggested that men who started with a low-normal sperm count and who were older required more time to recover (10). Another study examining more than 14,000 semen samples from Globe Health Organization (WHO) studies in which androgens were evaluated as a potential male person contraceptive found that sperm production afterward therapy was simply approximately 85% of pre-treatment concentrations (11). The literature too suggests that men who have been on high-dose TTh for longer periods volition crave longer to recover normal sperm production (12, 13).
Human chorionic gonadotropin (hCG) and selective estrogen receptor modulators (SERMs) are constructive at restoring spermatogenesis lone and in combination (12, xiv–17). The efficacy of hCG is attributed to its structural similarity to LH. SERMs potentiate spermatogenesis by inhibiting negative feedback by estrogen, thereby raising GnRH and gonadotropin levels and increasing downstream testosterone production. Numerous protocols combining hCG and SERMs are available for the restoration endogenous testosterone in testosterone-suppressed men. Ishikawa et al. used 5000 IU of hCG three times a week for three–6 months, in combination with recombinant FSH supplementation, with recovery of spermatogenesis observed in 44–100% of patients (xviii). hCG doses described in the literature range from 3,000 – 10,000 IU, administered 2–3 times per week (8, 13, 15, 18, 19). In a retrospective chart review of azoospermic or severely oligospermic men, Wenkler et al. observed return of spermatogenesis in a mean of 4.vi months with a hateful density of 22 meg sperm / mL in 95.ix% of subjects receiving hCG 3000 IU every other day, along with either FSH, clomiphene citrate, tamoxifen, or anastrozole (12). In another retrospective review past Coward et al., men previously on TTh and seeking vasectomy reversal were treated with loftier-dose hCG (3000 IU every other twenty-four hour period) and clomiphene citrate, with 83% having normalization of LH, FSH and testosterone levels (fifteen).
Previous studies analyzed only patients who had been on testosterone for a brusk duration, for contraception purposes, or who were eugonadal at the time if TTh initiation; our study analyzes men with a prolonged duration of TTh utilize and focuses on men who were cryptozoospermic or azoospermic at abeyance of TTh. The primary objective of the present study is to determine the factors that influence sperm recovery afterward presumed testosterone-associated infertility.
Textile AND METHODS
Patient Choice
After institutional review board approval, we retrospectively reviewed the records of 66 men with testosterone-associated infertility who were evaluated at a single bookish infertility clinic betwixt 2004 and 2015. Men were included if they presented for infertility, were 18 years or older, had been on testosterone for a recorded duration, and were establish to exist azoospermic or cryptozoospermic (<1 million sperm/mL) at the fourth dimension of TTh cessation. In addition they must have ceased TTh and began hCG therapy within a single visit, and had a to the lowest degree one follow-up semen analysis. Men were excluded if they had a history of vasectomy, obstructive azoospermia, or a known chief cause of testicular failure such as chromosomal abnormalities, Y-chromosome microdeletions, history of testicular trauma or infection, or history of cryptorchidism. No men included in the analysis were concurrently on recombinant FSH. Age at time of T cessation, total duration of TTh use, route of TTh, elapsing and dosage of hCG therapy, utilise and blazon of selective estrogen receptor modulators (SERM), serum levels of testosterone, FSH, and LH at time of presentation, and sperm concentration at presentation were recorded and compared.
Treatment
At initial presentation, men underwent a concrete exam by a urologist with fellowship training in male reproductive medicine, also as evaluation of serum testosterone, LH, FSH, prolactin, and estradiol levels, and semen assay. Men were instructed to stop testosterone employ and begin a regimen of 3,000 IU of hCG administered subcutaneously three times per week. All men in this report were as well prescribed either clomiphene citrate or tamoxifen citrate. Patients were seen in follow-upward approximately every 3 months, with semen analyses and hormonal evaluation performed at each visit
Statistical Analysis
The main upshot measure was whether patients achieved a total motile sperm count (TMC) of greater than 5 million sperm during evaluation within half-dozen months or within 12 months of stopping TTh and beginning hCG therapy. This total motile count reflects the minimum number of sperm used for intrauterine insemination (IUI) at our institution. 2 binary variables (TMC >5 million reached inside 12 months or within 6 months) were created, which were the dependent variables of involvement.
Nosotros compared the patient characteristics between those who reached TMC > 5 meg within 12 months using the Student t exam for normally distributed continuous variables, the Isle of mann-Whitney U examination for non-parametric continuous variables, and the chi-square test or Fisher verbal examination for chiselled variables. Just duration of TTh was found to be a nonparametric variable.
Nosotros used a multivariate linear probability model to estimate the effects of diverse factors on successfully reaching a TMC of >5 million sperm. Six independent variables were used in the final model – three continuous variables (duration of TTh, age at TTh cessation, and testosterone level at presentation), and three chiselled variables (whether TTh was delivered by intramuscular injection, transdermal application, or pellet insertion; use of clomiphene or tamoxifen citrate; and presence of cryptozoospermia or azoospermia). We and so employ the results of this regression analysis to calculate the predicted probability of achieving a TMC > 5 million within 12 months and vi months at unlike ages and durations of TTh. For instance, to summate the predicted probability of success for a thirty year-old man with a TTh duration of 1 year, nosotros causeless every patient in our sample is 30 years former and was on TTh for ane year. Nosotros and so use the coefficients estimated from the regression to summate each patient's predicted probability of success. These probabilities were and then averaged across the entire sample to calculate the terminal predicted probability for those parameters. Nosotros repeat this process for each combination of historic period and duration of TTh. All statistical analysis was performed using STATA 14.i, with p<0.05 considered significant.
RESULTS
Sixty-6 men met criteria and were included in this analysis at 12 months. Table 1 shows the baseline characteristics of all men and is further stratified past those who successfully accomplished a TMC >5 million sperm inside 12 months and those who did not. The mean±SD age of the accomplice was 40.2±8.vii years, and the median duration of TTh was 2 years (range 0.17 – 25) years. Thirty-five men used intramuscular injections of testosterone, xx-two topical testosterone, and nine used pellets. Forty-six men (69.seven%) successfully achieved a TMC of 5 1000000 or greater within 12 months. For men with successful recovery of spermatogenesis, the hateful±SD age was 38.3±7.0 years and elapsing of TTh use was a median of i.67 (range 0.17 – 15) years. For men without successful recovery of spermatogenesis, the hateful±SD age was 44.0±10.seven years and median duration of TTh was 4.0 (range 0.25 – 25) years. The average TMC for men with a TMC > v million sperm within 12 months was 40.0±44.six million sperm, while the boilerplate for those men with a TMC < five million sperm was 1.8±1.6 million sperm. The boilerplate sperm density for men who achieved a TMC > 5 one thousand thousand sperm within 12 months was 33.9±36.8 million sperm/mL while the average sperm density for those with a TMC < five million sperm was iv.7±seven.1 million sperm/mL. Tabular array 2 denotes semen parameters, FSH, LH, and testosterone levels for each formulation of testosterone at baseline, at vi months, and at 12 months. Semen density and TMC increases at each evaluation, from baseline to half-dozen months to 12 months, demonstrating the waning outcome of testosterone over time.
Tabular array 1
Baseline characteristics and comparing of men with successful and unsuccessful sperm recovery.
| Biometric Features | All Men (n = 66) | Success (n = 46) | Failure (north = xx) | P-value |
|---|---|---|---|---|
| Age of men (y) | 40.ii (±8.7) | 38.iii (±7.0) | 44.8 (±10.5) | 0.018 |
| Time on TTh (y) | 2.0 (0.17–25) | 1.67 (0.17–15) | 4.0 (0.25–25) | 0.001 |
| Initial Hormone Analysis | ||||
| Initial T (ng/dl) | 632 (±369) | 656 (±387) | 577 (±327) | 0.654 |
| Initial FSH (mIU/mL) * | 1.3 (±3.0) | 1.ii (±3.one) | 1.6 (±two.5) | 0.372 |
| Initial LH (mIU/mL) * | 0.9 (±2.5) | 0.ix (±2.8) | 0.9 (±1.six) | 0.725 |
| Route of Testosterone | ||||
| Injection | 35 (53.0) | 23 (50.0) | 12 (threescore.0) | 0.654 |
| Topical | 22 (33.3) | 17 (37.0) | five (25.0) | |
| Pellets | nine (thirteen.vi) | half-dozen (13.0) | 3 (xv.0) | |
| SERM | ||||
| Clomiphene Citrate | 45 (68.2) | 32 (69.6) | xiii (65.0) | 0.859 |
| Tamoxifen Citrate | 21 (31.8) | 14 (xxx.four) | 7 (35.0) | |
| Fertility Diagnosis | ||||
| Azoospermia | 54 (81.eight) | 34 (76.i) | 19 (95.0) | 0.055 |
| Cryptozoospermia | 12 (18.2) | eleven (23.9) | one (five.0) |
Tabular array 2
Median hormone levels and semen parameters for patients receiving testosterone via intramuscular injection, transdermal, and pellets at baseline, six months, and 12 months.
| Initial Evaluation | Evaluation inside 6 months | Evaluation within 12 months | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testosterone Type | Subgroups | FSH | LH | Testosterone | Semen Volume | Semen Density | Semen Mobility | Full Motile Count | FSH | LH | Testosterone | Semen Volume | Semen Density | Mobility | Total Motile Count | FSH | LH | Testosterone | Semen Volume | Semen Density | Mobility | Full Motile Count |
| Injection Testosterone (northward = 35) | All Patients | 0.four (0.1–2.0) | 0.2 (0.02–0.5) | 630 (395–1030) | 2.five (1.5–3.5) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | 1.35 (0.8–4.0) | ii.4 (0.3–4.8) | 536 (245–585) | 2.five (i.five–iii.5) | 10.0 (5.iii–20.0) | l (33–65) | eleven.4 (iii.9–25.half-dozen) | three.0 (1.0–v.0) | 2.0 (0.3–4.0) | 490 (275–662) | 2.5 (1.five–3.0) | 11.6 (5.one–24.ix) | 45 (30–64) | 15.8 (three.nine–36.v) |
| <five TMC (north = thirteen) | 0.seventy (0.i–2.0) | 0.iii (0.08–0.half dozen) | 509 (431–638) | ii.8 (one.5–3.3) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | 2.0 (0.2–iii.5) | 0.6 (0.07–3.three) | 585 (561–612) | 1.8 (i.4–2.6) | four.6 (1.eight–half-dozen.iv) | 28 (25–40) | 2.2 (1.three– iii.half-dozen) | 2.0 (0.ii–iii.5) | 0.5 (0.06–iii.iii) | 578 (612–473) | 1.five (1.0–ii.4) | 3.6 (one.3–v.i) | 30 (25–40) | ii.1 (0.9–3.3) | |
| >5 TMC (n = 22) | 0.4 (0.one–0.7) | 0.one (0.01–0.4) | 772 (316 –1059) | two.25 (1.5–3.5) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | 1.0 (0.nine–5.0) | ii.viii (1.6–5.3) | 386 (233–561) | 2.v (2.0–3.vi) | 16.0 (21.seven–9.1) | lx (48–65) | 21.ii (ten.9– 36.4) | three.0 (1.0–half dozen.ii) | two.5 (one.2–3.8) | 394 (257– 639) | 3.0 (two.0–3.5) | 20.4 (9.2–32.ane) | 58 (44–65) | 29.8 (46.9–fourteen.nine) | |
| Topical Testosterone (northward = 22) | All Patients | 0.iii (0.07–0.6) | 0.1 (0.04–0.4) | 532 (371–774) | ii.4 (1.five–3.0) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | 1.4 (0.vii–two.6) | 0.9 (0.3–1.ix) | 418 (291–564) | 2.0 (one.one–2.4) | 17.2 (7.2–41.2) | 53 (43–sixty) | 9.7 (4.four–21.4) | ii.eight (0.ix–4.viii) | ane.seven (0.3–3.0) | 386 (265–551) | 2.0 (two.0–two.7) | 18.0 (6.7–47.6). | 50 (42–60) | 18.0 (5.6–61.eight) |
| <five TMC (northward = 6) | 0.iv (0.0–0.7) | 0.07 (0.03–0.iii) | 657 (512–816) | 3.25 (1.9–3.nine) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | one.3 (1.0–3.7) | ane.3 (0.vii–1.vii) | 499 (370–535) | 3.3 (2.0–4.0) | ane.six (0.v–4.6) | 44 (15–55) | i.95 (0.3–3.vii) | 5.5 (4.1–9.8) | 2.5 (1.eight–5.0) | 370 (221–499) | 2.7 (2.0–3.8) | 1.3 (0.6–two.4) | 40 (sixteen–52) | 1.2 (0.1–3.2) | |
| >5 TMC (northward = xvi) | 0.iv (0.09–0.7) | 0.1 (0.1–0.half-dozen) | 527 (312–721) | 2.0 (one.5–3.0) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | one.5 (0.vii–2.5) | 0.8 (0.three–2.v) | 402 (300–567) | 2.0 (ane.0–two.0) | 20.4 (16.3–47.6) | 55 (45–60) | eighteen.0 (8.8–27.vii) | two.0 (0.7–3.0) | 0.7 (0.3–three.0) | 386 (282–588) | 2.0 (2.0–ii.one) | 20.5 (16.3–57.2) | 53 (46–60) | 22.ix (nine.ii–71.7) | |
| Pellet Testosterone (northward=9) | All Patients | 0.seven (0.three–3.2) | 0.3 (0.2–1.4) | 559 (208–703) | 1.8 (1.ane–2.0) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | two.0 (0.2–5.six) | 0.two (0.ane–two.6) | 566 (278–777) | 1.5 (0.ix–2.0) | 14.5 (2.2–23.five) | 45 (31–52) | 4.48 (0.9–16.1) | 2.0 (0.2–five.6) | 0.24 (0.2–3.7) | 542 (367–707) | 2.0 (1.0–2.5) | 24.0 (32.vii–12.viii) | 40 (34–55) | 9.6 (one.three–45.0) |
| <v TMC (northward = three) | 0.8 (0.five–5.four) | 0.iv (0.3–2.2) | 460 (334–587) | 1.0 (0.six–1.5) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | two.0 (0.7–3.half-dozen) | 0.vii (0.2–three.8) | 422 (216–716) | two.0 (1.0–2.0) | 1.5 (0.viii–4.5) | 30 (25–50) | 0.75 (0.4–one.two) | ii.0 (one.1–10) | 0.24 (0.2–6.one) | 566 (422–866) | ane.0 (0.vii–2.0) | four.5 (two.6–8.iii) | thirty (15–40) | one.2 (0.half dozen–1.3) | |
| >5 TMC (n = half dozen) | 0.7 (0.5–4.0) | 0.iv (0.ii–1.6) | 459 (207–673) | 1.v (1.0–two.0) | 0.0 (0-0) | 0.0 (0-0) | 0.0 (0-0) | two.nine (0.two–six.9) | 0.ii (0.i–2.i) | 707 (492–777) | 1.0 (0.8–2.0) | 24.0 (21.9–27.ii) | 53.0 (40–54) | 18.3 (9.half-dozen–23.5) | 2.6 (0.4–5.three) | 1.viii (0.2–three.v) | 500 (390–666) | ii.0 (1.3–2.4) | xxx.0 (24.8–52.1) | 48 (36–67) | 39.4 (15.7–78.4) | |
When comparison the differences between men who did and did non have successful recovery of spermatogenesis, age (p=0.018) and elapsing of TTh (p=0.006) were identified every bit significant predisposing factors. Route of testosterone assistants, initial serum testosterone level, type of SERM used and initial sperm concentration were not found to exist significant predictors of sperm recovery. Multivariate linear regressions were performed in social club to determine the magnitude of effect on the likelihood of success at both half dozen and 12 months; correlation coefficients are reported in Table 3. Supplemental Table 1 compares the issue of a multivariate linear regression including limited predictors with a multivariate linear regression with an expanded number of predictors, demonstrating that the expanded model accounts for a larger proportion of the variance in sperm recovery. Results presented here use the results of the expanded regression.
Table 3
Multivariate linear regression.
| six Calendar month Analysis | 12 Calendar month Analysis | |||||
|---|---|---|---|---|---|---|
| Variable | Coefficient (SE) | 95% CI | P-value | Coefficient (SE) | 95% CI | P-value |
| Time on TTh (years) | −0.0555 | (−0.0771, −0.0339) | <0.001 | −0.0306 | (−0.0555, −0.0057) | 0.017 |
| Age (years) | −0.0163 | (−0.0298, −0.0028) | 0.019 | −0.0171 | (−0.0308, −0.0034) | 0.015 |
| Initial T | 0.0002 | (−0.0001, 0.0005) | 0.176 | 0.00002 | (−0.0002, 0.0002) | 0.866 |
| Clomiphene citrate | −0.0641 | (−0.3045, 0.1763) | 0.595 | 0.0094 | (−0.2179, 0.2366) | 0.935 |
| Cryptospermic | 0.184 | (0.0700, 0.4390) | 0.152 | 0.2180 | (−0.006, 0.4410) | 0.056 |
| Type of Testosterone (Reference: Injection) | ||||||
| Transdermal | 0.0451 | (−0.2154, 0.3055) | 0.730 | 0.124 | (−0.1380, −0.3870) | 0.347 |
| Pellet | 0.177 | (−0.076, 0.430) | 0.166 | 0.163 | (−0.1100, 0.4360) | 0.237 |
Elapsing of TTh, age at TTh cessation, and initial sperm concentration were significant predictors for successfully reaching a TMC of 5 million within 12 months. Duration of TTh has a correlation coefficient of −0.0306 (ρ = 0.017; 95% CI −0.0555, −0.0057), suggesting that the probability of reaching a TMC of 5 million sperm decreases past 3.06% for each additional twelvemonth of TTh. Age has a correlation coefficient of −0.0171 (ρ = 0.015; 95% CI −0.0308, −0.0034), which suggests that the probability of reaching a TMC of 5 meg decreases by 1.71% for every year of age.
The regression analysis was performed for sperm recovery at 6 months using 59 observations. Similar to the assay of 12 calendar month data, duration of TTh (ρ = −0.0555, p < 0.001; 95% CI −0.0771, −0.0339) and age (ρ = −0.0163, p = 0.019; 95% CI −0.0298, −0.0028) were identified as significant negative predictors of successful sperm recovery at 6 months. Using the probabilities generated from this linear probability model, the likelihood of sperm recovery at 12 and 6 months based on a man'due south age and duration of TTh was calculated (Figures 1a and 1b).
(A) Probability of achieving a full motile count greater than 5 meg sperm inside 12 months of TTh cessation. (B) Probability of achieving a total motile count greater than five million sperm inside 6 months of TTh cessation.
Give-and-take
Currently, no guidelines are available discussing the direction of men presenting with infertility that is presumed to be associated with testosterone use. Furthermore, it is unclear how before long later on abeyance of testosterone that adequate spermatogenesis should be anticipated. The results of this report facilitate doc counseling of men presenting with azoospermia or cryptozoospermia presumably due to TTh, and provide a means to estimate the likelihood of recovered spermatogenesis at 6 and 12 months afterwards discontinuing TTh. The coefficients for the bear on of age are similar at both 6 and 12 months (−0.016 and −0.017), indicating that age has a durable, long-lasting outcome on sperm production and recovery of spermatogenesis. In contrast, the contribution of the elapsing of TTh decreased by approximately fifty% betwixt the 6 and 12 calendar month analyses (−0.055 vs −0.030), suggesting that the deleterious bear on of TTh on spermatogenesis diminishes with increasing time off of testosterone.
TTh suppresses the hypothalamic-pituitary-gonadal axis and inhibits spermatogenesis within 3.5 months in about men (10, twenty–22). The present study examined the successful return of spermatogenesis afterward discontinuation of TTh and initiation of high-dose hCG and SERM therapy. We found that cryptozoospermic men had a college likelihood of successful recovery of spermatogenesis when compared with azoospermic men at 12 months simply not at half-dozen months. Of azoospermic men, only 64.eight% accomplished a TMC >5 million sperm at 12 months, compared with 91.7% of cryptozoospermic men. Thus, sperm recovery progresses at similar rates in both groups during the the first half dozen months, but cryptozoospermic men have a higher likelihood of successful recovery of spermatogenesis inside 12 months.
In a preliminary written report, we demonstrated that hCG therapy promotes sperm recovery afterwards presumed testosterone-associated infertility (12). In the present study, important new findings are observed. Our preliminary work divers recovery of spermatogenesis in azoospermic patients equally the presence of any sperm and as any increment in sperm count for oligospermic patients. Our current report sets a more clinically relevant criterion for sperm recovery – the desirable number of total motile sperm required for IUI. Furthermore, our preliminary work did not evaluate the effects of total duration of TTh, which are more than clearly outlined. In the nowadays study, our inclusion criteria are stricter and describe from a larger cohort of men, facilitating a more rigorous set of conclusions, and we concurrently assess factors that influence sperm recovery. Near studies that have examined fourth dimension to recovery of spermatogenesis after TTh accept used testosterone every bit a male contraceptive in eugonadal men for upwardly to xviii months (twenty–24). In a pooled analysis of 30 hormone contraception studies encompassing 2,023 men, Liu et al. found age, initial testosterone level, initial LH level, full elapsing of testosterone, initial semen book and density, and type of testosterone to exist meaning predictors for recovery of spermatogenesis (10). Withal, this study examined men that were in tightly controlled clinical trials, were eugonadal prior to TTh, and were only on testosterone for less than one twelvemonth on average, limiting the generalizability of the results to hypogonadal men on longer-duration TTh (8). Nevertheless, the probabilities of recovery of spermatogenesis in the nowadays study are comparable to those observed by Liu et al. (ten). Liu et al. calculate a ninety% gamble of recovery to xx meg sperm / ml 12 months after abeyance of testosterone with a mean cohort historic period of 31.8 years and elapsing of testosterone treatment of ix.45 months. This probability is like to our calculated probability of a ninety.0% chance of achieving a TMC >5 one thousand thousand sperm at 12 months for a 30-yr onetime man with a 1 year elapsing of TTh yet Liu et al. find a lower average sperm density than our 33.nine meg sperm/mL boilerplate. When comparing probabilities of sperm recovery at 6 months duration of TTh, those calculated by Liu et al. are lower than those calculated by our model. Our increased probabilities may be owing to accelerated sperm recovery from hCG and SERM therapy.
While the only meaning predictors in our univariate analysis were time on testosterone and historic period, nosotros included initial T levels, route of T administration, and initial oligospermia as Liu et al. demonstrated in a much larger population that these factors are meaning; additionally, the inclusion of these variables strengthened the fit of our model. However our model differs from Liu et al. in that our model calculates probabilities for recovery of spermatogenesis for a wider range of ages and longer duration of testosterone in a population of men for whom these data will provide a meaningful ground for patient counseling.
A factor in the growing prevalence of testosterone-associated infertility is the mistaken view that testosterone tin can better a human being's fertility (7). Equally such, is essential that physicians counsel patients that testosterone will reduce their fertility and that longer durations of testosterone or avant-garde age will prolong fourth dimension to recovery of spermatogenesis. For men who desire futurity fertility, physicians should consider a baseline semen analysis prior to initiating TTh. This will ensure that men with underlying testicular dysfunction are identified prior to TTh, which could otherwise derange the interpretation of semen analyses while on post-TTh treatment.
The present study has several strengths and limitations. This is the kickoff study to examine sperm recovery after long-term TTh. We observed that both historic period and duration of TTh are predictors of recovery of spermatogenesis and present a model that facilitates take chances stratification across a broad range of ages and TTh durations. Nevertheless, the retrospective nature of the written report limits the impact and generalizability of the data. Importantly, we exercise non have semen analyses or FSH levels for these men prior to starting testosterone therapy, limiting our ability to discern underlying testicular dysfunction prior to initiation of TTh. While nosotros excluded men with known genetic or other known causes of infertility, we cannot conclude that all men included in this analysis were azoospermic or cryptospermic solely due to testosterone-induced infertility. Our model, however, is notwithstanding clinically useful as many patients who present with infertility that is presumed to be associated with testosterone use practice non have a semen analysis prior to initiating testosterone use. Additionally, our strict inclusion criteria limited the number of men included in this analysis. Finally, the dependent variable in our analysis is whether men successfully achieved a TMC > five million sperm within 6 or 12 months; all the same, we did non discover each subject'south TMC at exactly six or 12 months later on initiation of HCG/SERM therapy, just rather the semen analysis occurred within or upwardly to vi and 12 months after therapy initiation. Therefore, it is likely that we underestimate the effects of the predictor variables on TMC recovery.
Determination
The increased utilize of TTh in younger men has led to a rise in testosterone-associated infertility. In our retrospective study of 66 men with testosterone-associated infertility who ceased TTh and began high-dose hCG and/or SERM therapy, we identified age and duration of TTh equally significant predictors for the recovery of spermatogenesis at 6 and 12 months afterward TTh cessation. Using our predictive model, physicians can counsel men regarding the likelihood of recovery of spermatogenesis at half dozen and 12 months subsequently TTh abeyance. Older men on long-term TTh in particular should be counseled regarding the lower probability of successful recovery of spermatogenesis.
Supplementary Textile
01
Acknowledgments
Funding
A.W.P. is a National Institutes of Health K12 Scholar supported past a Male Reproductive Health Research Career Development Doc-Scientist Award (HD073917-01) from the Eunice Kennedy Shriver National Institute of Kid Health and Man Evolution Plan (to Dolores J. Lamb).
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers nosotros are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before information technology is published in its concluding citable grade. Please note that during the product process errors may exist discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
REFERENCES
i. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2010;95:2536–2559. [PubMed] [Google Scholar]
two. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal furnishings of crumbling on serum total and free testosterone levels in salubrious men. Baltimore Longitudinal Written report of Crumbling. The Journal of clinical endocrinology and metabolism. 2001;86:724–731. [PubMed] [Google Scholar]
three. McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. European urology. 2007;52:389–396. [PMC complimentary article] [PubMed] [Google Scholar]
four. Nguyen CP, Hirsch MS, Moeny D, Kaul Due south, Mohamoud M, Joffe HV. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. The New England journal of medicine. 2015;373:689–691. [PMC free article] [PubMed] [Google Scholar]
5. Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. The Periodical of clinical endocrinology and metabolism. 2014;99:835–842. [PMC costless article] [PubMed] [Google Scholar]
6. Kolettis PN, Purcell ML, Parker Westward, Poston T, Nangia AK. Medical testosterone: an iatrogenic cause of male infertility and a growing problem. Urology. 2015;85:1068–1072. [PubMed] [Google Scholar]
7. Ko EY, Siddiqi K, Brannigan RE, Sabanegh ES., Jr Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association. The Journal of urology. 2012;187:973–978. [PubMed] [Google Scholar]
8. McBride JA, Coward RM. Recovery of spermatogenesis post-obit testosterone replacement therapy or anabolic-androgenic steroid use. Asian periodical of andrology. 2016;18:373–380. [PMC free article] [PubMed] [Google Scholar]
9. MacIndoe JH, Perry PJ, Yates WR, Holman TL, Ellingrod VL, Scott SD. Testosterone suppression of the HPT axis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 1997;45:441–447. [PubMed] [Google Scholar]
10. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery subsequently hormonal male contraception: an integrated analysis. Lancet (London, England) 2006;367:1412–1420. [PubMed] [Google Scholar]
11. Ly LP, Liu PY, Handelsman DJ. Rates of suppression and recovery of homo sperm output in testosterone-based hormonal contraceptive regimens. Homo reproduction (Oxford, England) 2005;twenty:1733–1740. [PubMed] [Google Scholar]
12. Wenker EP, Dupree JM, Langille GM, Kovac J, Ramasamy R, Lamb D, et al. The Apply of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Employ. The periodical of sexual medicine. 2015;12:1334–1337. [PubMed] [Google Scholar]
13. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and man menopausal gonadotropin. Fertility and sterility. 2003;79(Suppl 3):1659–1661. [PubMed] [Google Scholar]
14. Liu PY, Turner L, Rushford D, McDonald J, Baker HW, Conway AJ, et al. Efficacy and prophylactic of recombinant man follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for consecration of spermatogenesis and fertility in gonadotrophin-scarce men. Human reproduction (Oxford, England) 1999;14:1540–1545. [PubMed] [Google Scholar]
15. Coward RM, Mata DA, Smith RP, Kovac JR, Lipshultz LI. Vasectomy reversal outcomes in men previously on testosterone supplementation therapy. Urology. 2014;84:1335–1340. [PubMed] [Google Scholar]
16. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and sterility. 2014;101:1271–1279. [PubMed] [Google Scholar]
17. Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, et al. Depression-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. The Periodical of clinical endocrinology and metabolism. 2005;90:2595–2602. [PubMed] [Google Scholar]
18. Ishikawa T, Ooba T, Kondo Y, Yamaguchi Thou, Fujisawa M. Assessment of gonadotropin therapy in male hypogonadotropic hypogonadism. Fertility and sterility. 2007;88:1697–1699. [PubMed] [Google Scholar]
19. Gill GV. Anabolic steroid induced hypogonadism treated with man chorionic gonadotropin. Postgraduate medical periodical. 1998;74:45–46. [PMC free article] [PubMed] [Google Scholar]
20. Hay CJ, Brady BM, Zitzmann Grand, Osmanagaoglu Chiliad, Pollanen P, Apter D, et al. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. The Periodical of clinical endocrinology and metabolism. 2005;90:2042–2049. [PubMed] [Google Scholar]
21. Kinniburgh D, Zhu H, Cheng Fifty, Kicman AT, Baird DT, Anderson RA. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Human reproduction (Oxford, England) 2002;17:1490–1501. [PubMed] [Google Scholar]
22. Amory JK, Anawalt BD, Bremner WJ, Matsumoto AM. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male person contraceptive evolution. Journal of andrology. 2001;22:1053–1060. [PubMed] [Google Scholar]
23. Turner L, Conway AJ, Jimenez 1000, Liu PY, Forbes E, McLachlan RI, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. The Periodical of clinical endocrinology and metabolism. 2003;88:4659–4667. [PubMed] [Google Scholar]
24. Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in 2 multinational clinical studies. World Health System Chore force on Methods for The Regulations of Male Fertility. International journal of andrology. 1995;18:157–165. [PubMed] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292276/
Enregistrer un commentaire for "Will Hcg Make You Fertail Again in Men"